India, Oct. 21 -- image credit- freepik

Nucelion Therapeutics, a specialised cell and gene therapy contract research, development, and manufacturing organization (CRDMO), and VeGen Bio, a Hyderabad-based precision oncology company, have announced a strategic collaboration for the technology transfer, clinical manufacturing, and commercial production of innovative cell therapies in India.

Under the agreement, Nucelion, a wholly owned subsidiary of Bharat Biotech, will serve as the technology transfer and clinical- and commercial-stage manufacturing partner for VeGen Bio's lead candidate, VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma into its single-site GMP manufacturing facility, designed to meet...